Axela Biosensors ( and BioCheck ( inked a licensing and supply agreement for clinical reagents that will be commercialized into biomarker assays on Axela’s dotLab™ System.

An initial set of research assays will be focused on protein biomarker analysis. Axela intends to further develop these into individual and multiplexed clinical diagnostic panels. The majority of the reagents that will be transferred to Axela’s platform are currently offered as in vitro diagnostic products by BioCheck.

Next articleUMMZ Periodical Cicada Page